CAR-T therapy successfully used to treat autoimmune disease

CAR-T therapy

CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS). 

CAR-T, which uses genetically altered immune cells to destroy cancer cells, has revolutionised treatment of some blood cancers since it was introduced in 2017. 

Researchers at Washington University School of Medicine in St Louis have shown that the same immunotherapy approach can be used in autoimmune diseases, which are often debilitating and difficult to treat. 

“We were able to use CAR-T cells to eliminate just the immune cells that are causing the autoimmunity and not other immune cells you might need to protect against viruses or other infection,” said co-senior author Chyi-Song Hsieh, the Alan A and Edith L Wolff Professor of Rheumatology and a professor of medicine and of pathology & immunology. 

MS is marked by rogue T cells that trigger the destruction of myelin, the protective covering over nerves. The researchers set out to create CAR-T cells equipped to seek out and destroy the rogue T cells that cause MS. 

“Having MS can really erode your quality of life, and while current therapies slow down the course of the disease, they don’t cure it and they have side effects,” said co-senior author Gregory F Wu, an associate professor of neurology and of pathology & immunology. “I believe that this is a fully treatable disease, and CAR-T cells may be the way toward much better therapeutics.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free